Almirall gets FDA approval for migraine drug
MADRID, June 3 (Reuters) - Spanish pharmaceutical firm Almirall (ALM.MC: Quote, Profile, Research, Stock Buzz) on Wednesday said its Almotriptan migraine drug had gained U.S. Food and Drug Administration approval for adolescents.
The drug -- marketed with U.S. partner Johnson & Johnson's (JNJ.N: Quote, Profile, Research, Stock Buzz) Ortho-McNeil Janssen Pharmaceuticals -- was already sold to treat migraines in adults, but is the first of its kind to be approved by the FDA for adolescents, Almirall said.
"This is a huge step for Almirall and our North American partner as it shows our commitment to giving adolescents with migraines a treatment that has not existed to date," it said.
Almirall's patent on Almotriptan in the United States has been extended to November 2015.
June 04, 2009